Efficacy and safety of semaglutide versus dulaglutide as add-on to metformin in subjects with type 2 diabetes

Trial Profile

Efficacy and safety of semaglutide versus dulaglutide as add-on to metformin in subjects with type 2 diabetes

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2018

At a glance

  • Drugs Semaglutide (Primary) ; Dulaglutide
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms SUSTAIN 7
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 01 Feb 2018 Results from this trial published in The Lancet Diabetes & Endocrinology, according to a Novo NOrdisk media release.
    • 01 Feb 2018 Results presented in a Novo Nordisk media release.
    • 01 Feb 2018 Primary endpoint (Change in HbA1c) has been met, according to a Novo Nordisk media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top